SciSparc Ltd.

SPRC

IL0010951403

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-16 pm EST			5-day change	1st Jan Change
1.070 ^USD	+1.90%		-26.21%	-21.32%

Jan. 13	SciSparc Subsidiary to Acquire Endoscopic Patents of Xylo Technologies in All-Stock Deal	MT
Dec. 01	Scisparc plans on entering the multi-billion-dollar GERD device market with acquisition of an approved IP portfolio	RE

Clearmind Says US Patent Application Published Targeting Binge Behavior Disorders

Published on 10/20/2025 at 08:13 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about SciSparc Ltd.

Jan. 13	SciSparc Subsidiary to Acquire Endoscopic Patents of Xylo Technologies in All-Stock Deal	MT
Dec. 01	Scisparc plans on entering the multi-billion-dollar GERD device market with acquisition of an approved IP portfolio	RE
Nov. 26	Scisparc to acquire treasury of patents for innovative medical endoscopy systems	RE
Nov. 26	Scisparc shares climb 27.5% premarket; co says will buy a treasury of patents, trademarks and intellectual property rights from Xylo	RE
Nov. 25	SciSparc Ltd. entered into a binding term sheet to acquire Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd.	CI
Nov. 25	Top Premarket Decliners	MT
Nov. 20	SciSparc Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 18	SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-10-23	Scisparc announces closing of the sale to N2off of majority-owned subsidiary Mitocarex, advancing drug discovery for resistant cancers including pancreatic and non-small cell lung cancer	RE
25-10-23	SciSparc Ltd. Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery	CI
25-10-20	Clearmind Says US Patent Application Published Targeting Binge Behavior Disorders	MT
25-10-20	SciSparc-Clearmind collaboration leads to publication of U.S. Patent Application targeting binge behavior disorders	RE
25-10-20	SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders	CI
25-10-19	N2OFF, Inc. completed the acquisition of MitoCareX Bio Ltd from SciSparc Ltd., Alon Silberman, Ciro Leonardo Pierri and others.	CI
25-10-06	SciSparc Ltd. cancelled the acquisition of remaining stake in Automax Motors Ltd.	CI
25-10-06	Scisparc Ltd. announces framework agreement regarding merger with AutoMax Motors	RE
25-09-30	Top Premarket Gainers	MT
25-09-29	Scisparc N2off shareholders approve merger with Scisparc's majority owned subsidiary Mitocarex	RE
25-09-25	N2OFF Shareholders Approve Acquisition of MitoCareX Bio	MT
25-09-25	N2off stockholders approve merger with drug discovery company targeting resistant cancers including pancreatic and non-small cell lung cancer	RE
25-09-25	SciSparc Ltd. Announces Board Appointments	CI
25-09-25	Scisparc Ltd. Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize Ai Drug Discovery	CI
25-09-25	SciSparc Ltd. Announces Management Appointments	CI
25-09-25	Top Midday Gainers	MT
25-09-25	SciSparc to Launch 3D Protein Modeling With Quantum Computing; Shares Rise	MT

Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Employees

Sector

Pharmaceuticals

More about the company